Primary immunodeficiencies in Tygerberg Hospital and on the national PID Registry, South Africa by Van Velden, Mia
Primary immunodeficiencies in Tygerberg Hospital and on the national PID Registry, South 
Africa 
M van Velden 
Dissertation presented in fulfilment of the requirements for the degree of Master of Medicine at 
Stellenbosch University 




By submitting this thesis electronically, I declare that the entirety of the work contained therein is my 
own original work, that I am the sole author thereof (save to the extent explicitly stated otherwise), that 
reproduction and publication thereof by Stellenbosch University will not infringe any third party rights 
and that I have not previously in its entirety or in part submitted it for obtaining any qualification. 
I, the undersigned, hereby declare that the work contained in this assignment is my original work and 
that I have not previously submitted it, in its entirety or in part, at any university for a degree. 
Mia van Velden 
Date: December 2019 
Copyright ©2019 Stellenbosch University 





Introduction: Little is known about the prevalence of primary immunodeficiencies (PID) in South 
Africa. The purpose of this study was to describe the profile and spectrum of patients affected by PID 
referred to the Tygerberg Hospital Immunology Service, situated in the Western Cape province of South 
Africa, during the past 25 years. 
Methods: This study entailed a retrospective descriptive analysis of the epidemiological data of patients 
with suspected PID referred to Tygerberg Hospital Immunology Service between 1 January 1991 and 
5 May 2016.  Data collected included date of birth, diagnosis, age at diagnosis, geographic origin, 
ethnicity, referral site, family history of PIDs, presenting features, immunological tests done, and 
outcome (alive or dead). The diagnosis was classified according to the International Union of 
Immunological Societies (IUIS) published in April 2014 and the European Society for 
Immunodeficiency published in July 2016 or listed as ‘other’. 
Results: The patient cohort included 500 patients between 0 and 60 years with a median age of 5 years 
(interquartile range=10). The majority of patients (70%) were from the Western Cape and were referred 
by paediatricians not linked to tertiary institutions (43%). The most common clinical presentation was 
recurrent respiratory tract infections (60%). The male to female ratio was 1.2:1. The main categories of 
PID, according to the IUIS criteria, were antibody deficiencies (52,80%), followed by complement 
deficiencies (19,80%), combined immunodeficiencies (7,12%), combined immunodeficiencies with 
associated syndromic features (6,25%), autoinflammatory disorders (3,40%), congenital defects of 
phagocyte number and/or function (4,20%), and defects in innate immunity (1,26%). There were no 
patients with phenocopies of PID disorders. The majority of patients were Caucasian (59,40%), who 
had antibody deficiencies (39,00%) as most common diagnosis. This was followed by 24,80% mixed-
race patients and 11,60% black African patients, who mostly had complement deficiencies (10,00% and 
4,00%, respectively).  
Conclusion: The median age of diagnosis of PID in this study was older than those in studies in other 
developing countries, but clinical presentation and types of PID were similar to reports from other 
developing countries with low rates of consanguinity. However, there was an increased number of 
patients diagnosed with complement deficiencies (specifically hereditary angioedema) in the Western 







Inleiding: Daar is weinig studies aangaande die voorkoms van primêre immuungebreke (PIG) in Suid-
Afrika. Die doel van dié studie was om die profiel en spektrum te bepaal van pasiënte met PIG wat oor 
die afgelope 25 jaar verwys is na die Tygerberg-immunologiekliniek in die Wes-Kaap. 
Metodes: Die studie is ’n retrospektiewe beskrywende analise van die epidemiologiese data van 
pasiënte, vermoedelik met PIG, wat tussen 1 Januarie 1991 en 5 Mei 2016 na Tygerberg Hospitaal 
verwys is. Die ingesamelde data het die geboortedatum, diagnose, ouderdom ten tye van diagnose, 
geografiese oorsprong, etnisiteit, verwysingsbron, familiegeskiedenis van PIG, presenterende 
simptome, of daar immunologiese toetse gedoen is, en die uitkoms (of die pasiënt lewend is/ gesterf 
het) ingesluit. Die diagnose is geklassifiseer volgens die riglyne van die Internasionale Unie van 
Immunologiese Gemeenskappe (IUIG), wat in April 2014 gepubliseer is, sowel as dié van die Europese 
Gemeenskap vir Immuungebrekkigheid, in Julie 2016 gepubliseer, of as ‘ander’ uitgelig. 
Resultate: Die pasiëntkohort het 500 pasiënte tussen 0 en 60 jaar met ŉ mediane ouderdom van 5 jaar 
(interkwartiel variasie =10) ingesluit. Die meerderheid (70%) van die pasiënte was van die Wes-Kaap 
en is deur pediaters verwys wat nie verwant is aan tersiêre hospitale in die Wes-Kaap nie (43%). Die 
algemeenste presenterende klagte was herhalende respiratoriese infeksies (60%). Die verhouding van 
mans tot vrouens was 1.2:1. Volgens die IUIG klassifikasie was die hoofkategorieë van PIG 
antiliggaamdefekte (52,80%), gevolg deur komplementdefekte (19,80%), gekombineerde 
immuungebrekkigheid (7,12%), gekombineerde immuungebrekkigheid met geassosieerde sindromiese 
kenmerke (6,25%), outo-inflammatoriese defekte (3,40%), kongenitale defekte van fagosietgetal en/ of 
-funksie (4,20%), en defekte in aangebore immuniteit (1,26%). Daar was geen pasiënte met fenokopieë 
van PIG nie. Die meerderheid van pasiënte was van Kaukasiese herkoms (59,40%) met antiliggaam 
defekte (39,00%) as hoofdiagnose. Dit is gevolg deur 24,80% pasiënte van gemengde herkoms en 
11,60% swart pasiënte – albei groepe het komplementdefekte (10% en 4% onderskeidelik) as 
hoofdiagnose gehad.  
Gevolgtrekking: Die mediane ouderdom ten tye van diagnose met PIG in hierdie studie was ouer in 
vergelyking met studies in ander ontwikkelende lande. maar kliniese presentering en PIG-tipes was 
soortgelyk aan die van ander ontwikkelende lande met ’n lae voorkoms van bloedverwantskap. Daar is 
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Chapter 1: Introduction 
1.1 Background 
Primary immunodeficiencies (PIDs) comprise nearly 300 different disorders in nine major 
categories.(1)(2) Very little is known of the prevalence of PID in Africa. Naidoo et al(3) concluded in 
a previous study of PIDs in the Western Cape, South Africa, that there was a need for research into the 
effective diagnosis of PIDs. Esser reported that PIDs were probably not only underdiagnosed, but were 
often diagnosed late.(4) Owen et al recently described the association of complement C5 and C6 
deficiency in the mixed-race and African populations in the Western Cape, concluding that complement 
deficiencies in South Africa were not rare(5).Bacille Calmette-Guerin(BCG) disease in human 
immunodeficiency virus (HIV)-negative patients was also an indicator of underlying PID, which was 
important in the South African context, where all children were vaccinated with BCG at birth.(4)(6) 
Missed or delayed diagnoses of children with PIDs may lead to serious morbidity and mortality, and 
can lead to a missed opportunity to improve the quality of their lives and even save lives.(7) 
South Africa has a high burden of infectious disease such as HIV and tuberculosis, which pose 
challenges for the diagnosis of PID.(8) These and other infectious diseases pose a limitation on 
resources available for rare diseases such as PIDs. They may also mask and delay a diagnosis of PID. 
This may result in the actual prevalence of PIDs in the country never being accurately determined.  
1.2 Problem statement and aim of research project 
The primary aim of the study was to describe the profile and spectrum of diagnoses of patients referred 
to Tygerberg Hospital immunology service during the past 25 years with suspected PID. This included 
the patients who were referred across the country to the Tygerberg Hospital immunology service and 
enrolled on the national PID Register. 
1.3 Brief chapter overview 
Chapter 2 reviews the literature, Chapter 3 describes the methodology including the study design, 
instruments used, data analysed, limitation of the data collection and ethical aspects of the data 






Chapter 2: Literature review 
2.1 Introduction 
Primary immune disorders are defects in the development and function of the human immune system. 
They are characterised by an increased susceptibility to infections, and some can present with 
autoimmunity or lymphoproliferation.(7)(9) Primary immunodeficiencies (PIDs) cause the patient to 
develop infections which are severe and persistent, presenting unusual types of organisms or course of 
illness, and may be associated with hypersensitivity reactions, autoimmunity and cancer.(10)(11)(12)  
PIDs are relatively rare conditions and are frequently diagnosed only at a late stage.(13)(14)(15) PID is 
often not diagnosed because the patient may present with non-specific signs which may easily be 
ascribed to other more common diseases.(7)(6) A delay in diagnosis can cause mortality in the infant 
and serious morbidity in the older child, with permanent organ damage and suffering.(7)(16) Accurate 
diagnosis is crucial to allow the earliest institution of appropriate and often lifesaving therapy such as 
bone marrow transplants or long-term immune replacement, while an incorrect diagnosis may lead to 
unnecessary high-risk interventions or years on costly treatment.(17) It is therefore crucial that 
physicians are able to recognise the warning signs (18)(16) that can indicate PIDs so that the correct 
investigations and treatment may follow. Warning signs for PID vary in different regions of the world. 
In South Africa helpful indicators that warrant further investigation for PIDs are disseminated BCG, 
recurrent meningococcal infections and atypical mycobacteria.(19)(1)(20) Important warning signs 
include a family history of primary immunodeficiency or failure to thrive. Other warning signs are 
related to persistent, recurrent, severe or unusual infections (e.g. four or more ear infections within one 
year; two or more serious sinus infections or pneumonias within one year; two or more months on 
antibiotics with little effect or a need for intravenous antibiotics to clear infections; recurrent, deep skin 
or organ abscesses; or two or more deep-seated infections, including septicaemia, persistent thrush in 
the mouth and fungal infection on the skin). 
Patient registries and databases constitute key instruments for the development of clinical research in 
the field of rare diseases, and the improvement of patient care and healthcare planning for better social, 
economic and quality of life outcomes. Such registries and databases are the appropriate way to pool 
scarce data for epidemiological and clinical research. They are vital to assess the feasibility of clinical 
trials, to facilitate the planning of appropriate clinical trials, to support the enrolment of patients and to 
assess the impact of new interventions.(21) In order to increase awareness, diagnosis and reporting of 
PIDs, the South African PID Registry was established in 2008. Once an accurate estimate of the burden 
of a disease is known, resource allocation, essential drug list inclusions and treatment such as 






2.2 Broad theory base 
2.2.1 Epidemiology  
The global prevalence of PIDs varies between 0.3 and 12 per 100 000 population, and is higher in areas 
with high rates of consanguinity. The prevalence in South Africa is unknown, but according to data 
reported in the PID Register these diseases are either missed or not reported. The possible reasons for 
underdiagnosis are that patients presenting with recurrent, persistent, severe or even unusual infections 
are treated without investigating the underlying cause, or the diagnosis is missed in the face of the 
overwhelming burden of similar clinical presentations of infectious diseases such as HIV and 
tuberculosis.(22) 
Data on epidemiology of PIDs are rapidly growing; however, as many countries have by now 
implemented registries for PIDs.(23) Registries are crucial to capture data on the spectrum of PID and 
treatment needs to inform healthcare providers and enable research collaborations.(8) Once an accurate 
estimate of prevalence of PIDs is known, it becomes a vital tool for advocacy for improved diagnostics 
and treatment. PID registries also allow identification of diseases more common in South Africa than 
elsewhere.(24) 
Because of the limited resources to diagnose and treat PID, a group of immunologists from four Latin 
American countries formed an organisation in 1993 called the Latin American Group for Primary 
Immunodeficiency Diseases (LAGID – later LASID). One of its aims was to include other Latin 
American countries and to create registries of PID in each participating country. After more than a 
decade since the creation of this group and its PID Registry, the result is impressive. The membership 
of the group has grown from the initial four to a total of 14 countries. Awareness, diagnosis and 
treatment of PIDs have improved as a result of annual discussions with international speakers, 
educational programmes and national scientific meetings with paediatricians. LASID, in cooperation 
with scientists in countries with well-established immunology and molecular biology laboratories, helps 
other countries with limited resources in the diagnosis of PID. LASID has also developed a parent 
support group and an online forum to keep members up to date with discussions regarding diagnosis 
and treatment options.(23) Other examples of PID registries in developing countries include the African 
Society for Immune Deficiencies (ASID) and the Iranian PID Registry (IPIDR).(25)(26) Some 
examples of registries and databanks in developed countries include the Reference Centre for PIDs 
established in France in 2005 (Centre de Référence Déficits Immunitaires Héréditaires), the European 
Society for Immunodeficiencies (ESID), the Jeffrey Modell Foundation, the Asian Primary 







To date there is still limited information regarding PID in South Africa, a developing country with a 
population of about 55.7 million nationals across nine provinces. The 2016 midyear estimated figures 
for race distribution in South Africa were black African 80,60%, mixed race 8,80%, Caucasian 8,10%, 
and Asian 2,50%.  
The South African PID Register was set up in affiliation with the paediatric PID clinical service in 2008 
and is based at Tygerberg Hospital. The national registry is coordinated through the National Health 
Laboratory Service at Tygerberg Hospital with private secretarial funding.(24)(27) The registry 
includes patients from both the public and private sector of South Africa who have consented to their 
data being collected for registry purposes. The service was further improved by adding a genetic 
counselling service and a molecular identification study in 2013. 
The only previous information on PID in South Africa was from an important study at a single 
institution, the Red Cross War Memorial Children’s Hospital in Cape Town, which reported the 
epidemiology of PID over a 27-year period between 1983 and 2009, and included 168 patients. The 
most common PIDs were antibody deficiencies (51%) (of which common variable immunodeficiency 
was the most common), followed by well-defined syndromes (24%), combined B and T cell deficiencies 
(11%), phagocytic disorders (5%), predominantly T cell defects (5%), complement defects (4%) and 
disorders of innate immunity (0,60%). There was a male predominance in all categories, except in well-
defined syndromes, where there was an equal gender distribution. There was a decline in the mean age 
of diagnosis of patients with PID (67 months to 35 months) over the period of 25 years.(3)  
Comparing research from other developing countries like Iran and Tunisia, there is a similarity in mode 
of presentation. A large study in Iran between March 2006 and March 2013 of 731 patients from 14 
medical centres  predominantly had patients with antibody deficiency (32,30%). This was followed by 
combined immunodeficiencies (22,30%) and thereafter congenital defects of phagocyte number, 
function or both (17,40%), syndromes (17,20%), auto-inflammatory disorders (5,20%), immune 
dysregulation (2,60%), defects in innate immunity (1,60%) and complement deficiencies (1,40%).(26)  
A report from Tunisia, covering 25 years (1988–2012) (Tunisian Registry of Primary 
Immunodeficiencies) included 710 patients. Of note was the high rate of consanguinity (58,20%) of 
families, as well as differences from Western countries owing to the large proportion of patients with 
combined immunodeficiencies and phagocyte defects in number and/or function. Combined 
immunodeficiency disorders were the most common (28,60%) followed by congenital defects of 
phagocyte (25,40%), immunodeficiency syndromes (22,70%), predominantly antibody deficiencies 
(17,70%), diseases of immune dysregulation (4,80%), defects of innate immunity (0,40%) and 
complement deficiencies (0,40%).(28) All three studies mentioned above (Tunisian, South African  and 






2.2.2 Classification of PID  
The aim of the classification of PIDs in categories is to provide a framework that not only demonstrates 
the scientific basis of these conditions, but assists clinicians in diagnosis. Classification also contributes 
to advising on appropriate ICD10 coding (World Health Organization International disease codes). 
These codes form the basis on which funding for healthcare is provided.  
The international classification, being the International Union of Immunological Societies Expert 
Committee for Primary Immunodeficiency (see Appendix 2 for IUIS April 2014), defines nine 
categories which are distinguished according to which component of the immune system is affected.(29) 
For each category, the condition is listed, along with the genetic defect, if known, and the major 
immunological abnormalities (and for some conditions the non-immunological abnormalities) 
associated with the disease. Since 2013 the IUIS also instituted a phenotypic classification, and is 
revised every two years. 
The nine IUIS categories are:(29) 
1. Combined immunodeficiencies 
2. Combined immunodeficiencies with associated or syndromic features 
3. Predominantly antibody deficiencies 
4. Diseases of immune regulation 
5. Congenital defects of phagocyte number, function, or both 
6. Defects in innate immunity 
7. Autoinflammatory disorders 
8. Complement deficiencies 
9. Phenocopies of PID 
Classification can be done by either using the IUIS or ESID criteria: 
Table 2.1: Definition of IUIS and ESID 
ESID (July 2016) IUIS (April 2014) 
 European Society of Immunodeficiencies 
(ESID; reviewed July 2016) 
 66 categories 
 International Union of Immunological 
Societies Expert Committee for Primary 
Immunodeficiency (IUIS; reviewed April 
2014) 






The extended classification and clinical diagnosis definitions of immunodeficiencies of the European 
Society of Immunodeficiencies (ESID) Registry (July 2016) has 66 categories (see Appendix 3). The 
ESID criteria are for patients with no genetic diagnosis, except for atypical severe combined immune 
deficiency (SCID) and DiGeorge syndrome where a known genetic defect and confirmation of criteria 
is mandatory.  
2.2.3 The 10 warning signs of primary immunodeficiency are:(18)(30)(16) 
1. One or more new ear infections within one year 
2. Two or more serious sinus infections within one year 
3. Two or more months on antibiotics with little effect 
4. Two or more pneumonias within one year 
5. Failure of an infant to gain weight or grow normally 
6. Recurrent, deep skin or organ abscesses 
7. Persistent thrush in mouth or fungal infection on skin 
8. Need for intravenous antibiotics to clear infections 
9. Two or more deep-seated infections including septicaemia 
10. A family history of PIDs 
    
Additional warning signs in use specifically to South African patients are:(13)  
1. BCG dissemination 
2. Recurrent meningococcaemia 
3. Unusual or recurrent mycobacterial infections  
2.2.4 Investigation of immunodeficiencies  
Investigation is guided by an in depth detailed medical history, clinical presentation with thorough 
examination and consideration of a causative organism.(1)(30)(31) A practical way to investigate PID 
is provided in Table 2.2, which is adapted from the four-step Jeffrey Modell Foundation(JMF) 
approach, as the four steps procedure is not always feasible for patients who travel long distances in 







Table 2.2: Primary Immunodeficiency investigation (modified from the Jeffrey Modell 
Foundation approach) 
First-stage testing  Example 
 Exclude chronic infection FBC and differential 
HIV, CMV, EBV, TB 
Quantitative immunoglobulins IgE, IgG, IgM, IgA 
Sweat test 
 
Second- and third-stage testing 
 
Complement screen CH50, C1qAb, C3, C4, C6, CH100, ACH 100, MBL, 
C1 inhibitor 
Lymphocyte phenotyping T helper cells, cytotoxic T cells, B cells, NK cells, 
Killer cells (using mAbs for CD3, CD4, CD8, CD19, 
CD16+56, CD18) 
Humoral testing IgG subclasses (IgG1, IgG2, IgG3, IgG4); B cell 
activation markers, memory B cells, specific antibody 
responses to protein antigens, 
response to polysaccharide vaccine 
T Cell function Mantoux skin test, Quantiferon gold TB test, T-spot 
TB test 
Lymphocyte proliferation in 
response to mitogens 
 
Phagocyte function tests Oxidative burst test, phagocytic index & chemotaxis, 
CD11, CD18, bacterial killing 
Fourth-stage: Confirmatory / 
Genetic tests with some examples  
 
Agammaglobulinaemia Bruton’s Tyrosine kinase; KRECS and TRECS (naïve B and T cells), 







(i) First-stage testing 
First-stage testing includes exclusion of chronic infection and causes of secondary immune deficiency 
such as human immunodeficiency virus (HIV), cytomegalovirus (CMV), Ebstein Barr virus (EBV), 
TB, coeliac disease, diabetes mellitus, cystic fibrosis and protein-losing states. First-line screening for 
primary immune defects includes a full blood count with a differential count and a smear, as well as 
testing of immunoglobulin levels.(32)(33) When evaluating the white cell subsets it is important to look 
at the absolute count rather than percentages and the respective ranges for age.(31) When measuring 
levels of major immunoglobulin classes (IgG, IgA, IgM and IgE), it is important to compare the results 
with age-matched reference intervals that are typically provided as 95% confidence intervals.(31)  
(ii) Second- and third-line testing (34) 
Second- and third-line testing should be dependent on suggestive history, symptoms and cultured 
organisms. Lymphocyte phenotyping by flow cytometry form part of the later screening tests of 
humoral, T cell and NK cell deficiencies. Absence of B cells with normal T cells and NK cells is found 
with agammaglobulinaemia, while reduced T cells are found in severe combined immunodeficiency 
syndrome (SCID).(35) 
The best screening test for defects in the classical complement pathway is doing a haemolytic 
complement activity assay (CH50) (classical pathway), whereas the AH50 assay screens for defects in 
the alternative pathway.(31) When the total immunoglobulin levels are only modestly decreased (or 
even normal), measurement of specific antibody responses is useful in confirming defective antibody 
production.(31) Functional analysis of B lymphocyte and IgG subclasses involves the analysis of 
antibody responses to protein antigens (e.g. antibody response to tetanus vaccine) and polysaccharide 
antigens (e.g. antibody response to Streptococcus pneumoniae polysaccharide vaccine). If the antibody 
response to a vaccine antigen is low, the patient should be vaccinated to ensure appropriate exposure, 
and antibody levels should be retested four weeks after vaccination.(31)(1)  
Immunoglobulin subclasses (IgG1, IgG2, IgG3 and IgG4) can be used in selected patients to delineate 
subclass deficiencies if IgG levels are normal but antibody responses are defective. Subclass 
deficiencies are also seen in patients with IgA deficiencies.(24) Functional analysis of T lymphocytes 
involve analysing cytokine production or proliferation. The Mantoux test is an in vivo delayed 
hypersensitivity response to a purified peptide derivative. T lymphocytes proliferate in response to 
antigens and mitogens.  
Functional analysis of the innate immune system, including phagocytic defects, measures chemotaxis 






pathogens), and the oxidative burst (intracellular killing) functions of neutrophils and 
monocytes.(22)(31) 
(iii) Fourth-line testing  
Fourth-line testing should be guided by an experienced clinician and preferably with a genetic 
counsellor. These tests may include enzyme measurements, cytokine studies and genetic investigations. 
Examples include specific Bruton’s tyrosine kinase assays to confirm agammaglobulinemia, CD40 
ligand for hyper-IgM syndrome, CD 11/18 determination for leucocyte adhesion deficiency and 
common gamma chain detection for X-linked SCID and an increasing number of genetic 
investigations.(24)(36) 
2.2.5 Treatment of immunodeficiencies 
Treatment of immunodeficiencies include prevention and treatment of infections, boosting of the 
immune system and treatment of the underlying immune deficiency and associated conditions.(13) 
Prevention of infections include prophylactic antibiotics or antifungals as determined by the pathogens 
involved. Penicillin is commonly used for late complement factor deficiencies, co-trimoxazole and 
itraconazole for chronic granulomatous disease and cotrimoxazole for T cell defects.(22) The use of 
live attenuated vaccines, e.g. oral polio, BCG, measles, mumps, rubella, varicella or rotavirus, in any 
patient with T cell or severe immunodeficiency is strictly contraindicated to prevent vaccine-associated 
disseminated infections. Live polio virus vaccination is also contraindicated in agammaglobulinaemia. 
Live vaccines should be avoided whenever there is a family history of severe PID.(22) 
Other general measures in treatment of patients with PID are prompt and aggressive treatment of 
infections, providing nutritional support (e.g. Zinc, Vit D and Vit A) and only using irradiated blood 
products for transfusions to prevent possible graft versus host disease, particularly for severe T cell 
defects.(22) Boosting or replacement of the immune system is done by subcutaneous or intravenous 
administration of gamma globulin (Ig) therapy (for patients with antibody and B lymphocyte 
deficiencies), gamma interferon (for patients with chronic granulomatous disorder with recurrent 
infections) and the very judicious use of growth factors.(37)(38)(39) 
Bone marrow transplant (BMT), now mostly referred to as haematopoietic stem cell transplant (HSCT), 
is curative in almost 75% of children affected by severe PIDs. In recent years the outcome of BMT and 
cure for PID has increased dramatically in dedicated centres with earliest diagnosis and access to the 
international donor pool, even with matched unrelated donors (MUDs). Besides the conventional 
indications for BMT (profound or absent T cell function, profound or absent natural killer function, 
known syndromes with T cell deficiencies), indications to BMT for PIDs affecting quality of life or 






Access to HSCT in the public and private sector in South Africa is limited, as a consequence of the lack 
of availability of local donors and also a lack of dedicated facilities with expertise.(13) Other available 
treatments indicated in specific disorders include cytokine therapy, enzyme replacement, colchicine and 
interleukin 1-blocking agents and an emerging list of biologic drugs.(1)  
The future of treatment of PID where molecular diagnosis can be confirmed (e.g. severe forms of T-
cell-related PID) is with gene therapy.(34) Gene therapy has been shown to be successful, as immune 
reconstitution was achieved in children with SCID. However, it is not yet routinely used as a therapeutic 
modality as it has caused leukaemia in some recipients.(22)(41)(34). The initiation of these leukemias 
was related to vector-mediated insertional mutagenesis and vector lower respiratory tract enhancer 
activation of endogenous proto-oncogenes such as LMO2, Bmi1 and CCND2(34). The first clinical 
trials performed with gamma retroviral vectors (c-RV) for adenosine deaminase severe combined 
immunodeficiency (ADA-SCID), X-linked SCID (SCID-X1) and Wiskott–Aldrich syndrome (WAS) 
showed that gene therapy is a valid therapeutic option in patients lacking an human leukocyte antigen-
identical donor. The occurrence of insertional oncogenesis in SCID-X1, WAS and chronic 
granulomatous disease (CGD) RV of earlier clinical trials prompted the development of safer vector 
construct based on self-inactivating (SIN) retroviral or lentiviral vectors (LVs).(42) No insertional 
mutagenesis events have been observed in more than 40 ADA-SCID patients treated so far in the context 
of different clinical trials worldwide, suggesting a favourable risk–benefit ratio for this disease. Gene 
editing for the defective gene is another future option of treatment which is already being trialled. 
2.3 Conclusion 
A review of PIDs diagnosed will give an indication of the profile of the patients in the Western Cape 
with PID. This will also increase awareness of PIDs in South Africa which will – it is hoped – result in 






Chapter 3: Method 
3.1 Research design  
The study is a retrospective descriptive analysis of the cohort of patients referred to the Tygerberg 
Hospital Immunology Service over the past 25 years (1 January 1991 to 5 May 2016). Tygerberg 
Hospital is one of two tertiary-level hospitals in the Western Cape, South Africa, and mainly receives 
referrals from the Western Cape, but also from the other eight provinces in the country. The patients 
were between the ages of birth and 73 years and were referred for suspected PID. Patient records were 
excluded from the study if age, presenting complaint or diagnosis were not captured.  
3.2 Data capture 
Data were obtained from the hard copies of the clinical records of patients seen at Tygerberg Hospital 
Immunology Service and from the South African PID Register. The data were de-identified, 
electronically captured by using REDCAP (research electronic data capture) offline on the Tygerberg 
Hospital premises, and later uploaded to the central REDCAP database. 
Diagnosis of immunological abnormalities was obtained from laboratory data retrieved from the 
National Health Laboratory Services (NHLS) and affiliated referral laboratories and interpreted by the 
clinician in charge of the service. PIDs were classified according to the nine categories as set out by the 
IUIS classification published April 2014 and the more extended classification of the ESID, published 
2016. The patients who could not be classified according to the IUIS or ESID classification were 
excluded, and an alternate diagnosis was captured. 
The variables that were captured included age; geographic origin; ethnicity; clinical presentation; source 
of referral; whether the patient was seen at Tygerberg Hospital (either in the clinic or in the ward) or 
consulted via telephone or email; whether there was a known family history of PIDs; diagnosis (IUIS/ 
ESID/ other); age of patient at diagnosis; whether immunological tests were done; date of first and last 






Table 3.1: Thirteen variables were captured from 871 patients 
Patient profile Immunology Service 
 Sex 
 Age at diagnosis 
 Geographic origin 
 Ethnicity 
 Family history 
 Presenting features 
 Diagnosis (IUIS and ESID) 
 Outcome 
 Source of referral 
 Mode of referral 
 Date of diagnosis 
 Immunological tests done 
 Whether patient is registered on the SA 
PID Register 
The exported data de-identified patient name, date of birth and folder number, linking the record to a 
unique study number and all data analyses were done without identifying data. The log identification 
key was securely kept, with access available only to the principal investigator, who had the use of a 
password-protected computer. 
Statistical analysis 
Descriptive statistics such as means, standard deviations, and proportions were calculated. Cross-
tabulation was done for categorical risk factors and outcomes such as clinical diagnosis and primary 
immune deficiency (PID). The association between these risk factors (i.e. sociodemographic and 
clinical presentations) and the various outcomes were assessed by a chi-square test.   
The prevalence of PID in the study group was estimated overall and reported with 95% confidence 
intervals. The time to PID diagnosis was calculated from the clinical records, and Kaplan-Meier graphs 
were used to compare graphically the time-to-event profile for various risk factors such as the sex of 
the patient. 
For ease of interpretation, the visual representation of the results were converted to a flowchart for the 
number of patients included, a histogram for the age of diagnosis, family history represented in a pie 
chart, source of referral and PID classification was converted to bar charts, pie charts and tabulations. 
 
Stata 15 was used for the calculations. 
3.3 Ethics 
The ethics status of the research protocol was approved by the Health Research Ethics Committee 






waiver of individual consent for patients that could not be traced. Permission was granted by the chief 
executive officer of Tygerberg Hospital to review the patient folders. The custodian of the PID Register 
gave consent for access to the records of patients who were referred to Tygerberg Hospital. The South 
African PID Register had already given ethics approval for data analysis (approval number N08/09/264) 
(“SA PID Register”). The exported data de-identified patient name, date of birth and folder number. 
The patients were assigned a unique study number in order to maintain anonymity. The log 
identification key was securely kept, with access available only to the principal investigator, who had 







Chapter 4: Results 
4.1 Section 1: Family history, sex and number of patients analysed 
Tygerberg Hospital received referrals from both the state and private healthcare sectors in the country. 
Over the past 25 years, 876 patients were referred to the immunology service with suspected primary 
immunodeficiency. Five patient files were excluded as they contained insufficient data (Figure 4.1). Of 
the 871 patients, 371 (42,59%) did not meet the criteria of PID in either the ESID or IUIS classification, 
though 14% had a positive family history of having a PID. The final study population of 500 patients 
was further analysed and 22,40% had a family history of PID (Figure 4.2), with a male to female ratio 
of 1.2:1 (sex was unknown in 0,40% of the cases). Of the 500 patients with PID, 316 were registered 
on the South African PID Registry. 
 
Figure 4.1: Number of patients in the study: Of the 876 files captured, 5 were excluded due to 
insufficient data.  Of the remaining 871 files, 500 patients were classified with a PID, and 316 of 



















Figure 4.2: Family history of patients referred to the clinic with confirmed primary 
immunodeficiency (n=500):  in 40% of patients with PID it was not noted whether there was a 
family history of PID or not, 38% had no family history and 22% had a known family history of 
PID 
4.2 Section 2: Age distribution of patients   
The median age of patients with PID was five years (interquartile range=10) (mean: 10 years; range: 1 
year 9 months till 60 years; Standard Deviation 12,6). The majority (60%) of patients were diagnosed 

















Figure 4.3: Box Plot of patients with PID (median  age 5 years, interquartile range=10, 25th quartile=2 
years, 75th quartlile=12 years, minimum  age=0, maximum age=60years)  
 
4.3 Section 3: Region of referral of patients 
The majority of patients with confirmed PID were from the Western Cape (69,60%), while 15% were 
from Gauteng, 4,80% from KwaZulu-Natal, 3% from Free State, 2,80% from Eastern Cape, 1,60% from 
Mpumalanga, 1,20% from Northern Cape, 1,20% from non-South African citizens, 0,60% from North 
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Figure 4.4 Region of referral of patients 
4.4 Section 4:  Source of referral 
As depicted in Figure 4.5, the majority (43%; n=216) of patients were referred by paediatricians not 
linked to tertiary institutions, while 26% (n=133) were referred by a paediatrician in a tertiary 
institution, 18% (n=90) by physicians in tertiary institutions, 8% (n=42) patients from physicians other 
than from tertiary institutions, 1% (n=6) from general practitioners, and 2% (n=13) from other (e.g. 















Figure 4.5: Source of referral of patients for evaluation of suspected primary immunodeficiency 
4.5 Section 5: Presenting features 
The presenting features were classified according to a selection of 10 common modes of presentation. 
The most common presentations were respiratory complaints (n=304;60%), followed by oedema 
(n=52;10%); gastrointestinal-related symptoms (GIT) (n=41;8%); central nervous system (CNS) 
disorders (n=38;7,5%); and skin infections or eczema (n=36;7%). The other modes of presentation 
included patients (n=32; 6%) who could not be classified in the nine common modes of presentation: 
namely patients who presented with septicaemia (n=25; 5%), those who were asymptomatic/carriers 
(n=17; 3,4%), those who had bone and joint complaints (n=17; 3,4%), and those who presented with 
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Figure 4.6: Presenting features of patients with Primary Immunodeficiency Disorders.  The 
presenting features were classified in these 10 categories as it was the most common groups. 
Some patients presented with more than one of the presenting features, thus the total 
percentages does not add up to 100%. 
4.6 Section 6: Classification (International Union of Immunological Societies Expert 
Committee for Primary Immunodeficiency 
The patients were classified according to the 10 categories of the International Union of Immunological 
Societies Expert Committee for Primary Immunodeficiency (IUIS) classification, of which the 10th 
category was classified as ‘none of the above’, and the 67 categories of the European Society for 
Immunodeficiencies (ESID) classification, of which the 67th category was ‘none of the above’. The 
majority (n=473; 95%) of the 500 patients could be analysed according to IUIS criteria 1 to 9. According 
to IUIS criteria the majority of patients (n=264; 52%) predominantly had antibody deficiencies (IUIS 
3), followed by complement deficiencies (IUIS 8) in 20% (n=94); a further 7% (n=33) had combined 
immunodeficiencies (IUIS 1); 6% (n=30) had combined immunodeficiencies with associated 
syndromic features (IUIS 2); and 4% (n=20) had congenital defects of phagocyte number, function or 
both (IUIS 5). The smallest three groups were 3,3% (n=16) of patients who had autoinflammatory 
disorders (IUIS 7); 2% (n=10) of patients with diseases of immune dysregulation (IUIS 4); and 1% 
(n=6) had defects in innate immunity (IUIS 6). There were no patients with phenocopies of primary 
immunodeficiency disorders (IUIS 9) (Figure 4.7).   
Pyrexia (n=15; 3%)
Asymptomatic/ carrier (N=17; 3,4%)
Bone and joint complaints (n=17; 3,4%)
Septicaemia (n=25; 5%)
Other (n=32; 6%)
Skin infections/ eczema (36; 7%)
CNS disorders (n=38; 7.5%)









Figure 4.7: Ethnicity and primary immunodeficiency according to the International Union of 
Immunological Societies Expert Committee for Primary Immunodeficiency criteria  
4.7 Section 7:  Ethnicity of patients 
Table 4.2 and Figure 4.8 summarises the PIDs in the different ethnic groups (n=473) according to the 
IUIS classification. Two Asian patients were not diagnosed according to IUIS criteria, leaving 473 for 
further analysis according to IUIS. The majority of patients with PID, 57,40%, were Caucasian, 
followed by 24,80% mixed race, 11,60% African, and 0,40% Asian, while race was unknown in 5,70% 
(Figure 4.6). The mixed-race and African population mostly had complement deficiencies (9,80% and 
3,80% respectively), followed by antibody deficiencies (3,20% and 6,80% of total PIDs) and combined 
immunodeficiencies with syndromic features (1,20% and 2%). The majority (42%) of the Caucasian 
patients with PID had antibody deficiencies (39% of total PIDs), followed by complement deficiencies 
(5,20%), combined immunodeficiencies (3%) and autoinflammatory disorders (2,60%).  
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African 0,8 1 3 0 0,6 0,2 0 4 0
Mixed Race 2 2 7 0,6 1 0,4 0,2 10 0
Caucasian 3 3,3 41 1 2 0,6 2,7 5 0
Unknown 0,8 0,2 4 0,2 0,2 0 0,4 0 0
























Table 4.1: Ethnicity and Primary Immunodeficiency Disorders (International Union of 
Immunological Societies Expert Committee for Primary Immunodeficiency criteria ) 
IUIS criteria African Caucasian Mixed race Unknown Total 
1 Combined 
immunodeficiencies 




6 13 10 1 30 (6%) 
3 Predominantly antibody 
deficiencies 
16 195 34 19 264 (56%) 
4 Diseases of immune 
dysregulation 
0 6 3 1 10 (2%) 
5 Congenital defects of 
phagocyte number, function 
or both 
3 10 7 0 20 (4%) 
6 Defects of innate 
immunity 
1 3 2 0 6 (1%) 
7 Autoinflammatory 
disorders 
0 13 1 2 16 (3%) 
8 Complement deficiencies 19 26 49 0 94 (20%) 
9 Phenocopies of primary 
immune deficiency 
disorders 
0 0 0 0 0 (0%) 
Total: absolute (percentage) 49 (10,0%) 281 
(59,40%) 
116 (24,5%) 27 (0.05%) 473 
4.8 Section 8: European Society for Immunodeficiencies (ESID) classification 
Nearly all patients (n=495; 99%) could be diagnosed with PID using the ESID classification. The most 
common diagnosis in 108 patients (21,7%) was antibody deficiency; 57 patients (11,4%) had hereditary 
angioedema; 46 patients (9,2%) had common variable immunodeficiency disorders; 35 patients (7%) 
had unclassified complement deficiencies; and 31 patients (6,7%) had well-defined immunodeficiency 
syndromes. There were 17 (3,5%) patients with SCID – an important group because of the high 
morbidity and mortality if diagnosed late. Because of routine vaccination with BCG at birth and the 
high incidence of tuberculosis in South Africa,(43) an important group was the patients with Mendelian 
susceptibility to mycobacterial diseases (n=7; 1,4%). The remaining five patients with PID were 






Table 4.2 European Society for Immunodeficiencies (ESID) classification  
PID category (ESID) Total number of patients Percentage 
   
Unclassified antibody deficiency 108 21,7 
Hereditary angioedema 57 11.4 
Common variable immunodeficiency disorder 46 9.2 
Agammaglobulinemia 35 7,0 
Unclassified complement deficiencies 35 7,0 
Transient hypogammaglobulinaemia of infancy 33 6,6 
Selective IgA deficiency 20 4,0 
Unclassified autoinflammatory disease 18 3.6 
Severe combined immunodeficiency 17 3.4 
Unclassified immunodeficiencies 16 3.2 
Specific IgG deficiency 14 2.8 
DiGeorge syndrome 13 2.6 
Combined immunodeficiency 11 2.2 
Chronic granulomatous disease 10 2,0 
HyperIgE syndrome 8 1.6 
Unclassified phagocytic disorders 7 1.4 
Defects with susceptibility to mycobacterial infection 7 1.4 
Isolated IgG deficiency 7 1.4 
Unclassified disorders of immune dysregulation 6 1.2 
Wiskott-Aldrich syndrome 6 1.2 
Unclassified defects of innate immunity 4 0.8 
Ataxic telangiectasia 3 0.6 
Cyclical neutropenia 2 0.4 
One patient (0,2%) in each of the following 
categories: 
12 2.4 
- Autoimmune lymphoproliferative syndrome 
- Chronic mucocutaneous candidiasis 
- complement component 2 deficiency 
- class switch recombination defects and hyperimmunoglobulin M syndromes 
- congenital neutropenia 
- familial hemophagocytic lymphohistiocytosis syndromes 
- FOXP3 deficiency 
- IPEX-like disease 
- mannose-binding lectin deficiency 
- Omenn syndrome 
- Selective CD4 cell deficiency 
- unclassified syndromic immunodeficiency 






4.9 Section 9: Immunological tests done 
The majority of patients (88%) were investigated with immunological tests, while 2% did not have any 
investigations done (already done prior to referral) and in 10% of patients the results were not recorded 
in the notes.  
4.10 Section 10: PID Registry 
Only 63% (n=316) of the 500 patients with PID were registered in the national PID register. Of the 
patients on the PID Registry, 90,5% (n=286) were still alive, 9,1% (n=29) were deceased and 1 patient’s 







Chapter 5: Discussion 
5.1 Summary of findings 
This is the first review of the patients referred to the Tygerberg Immunology Service over the past 25 
years, and adds to the knowledge of the patient profile of South African patients with PID. Since the 
study focused on patients referred to Tygerberg Hospital Immunology Service, the epidemiological 
information obtained provided data from a single, central hospital in South Africa. It is noteworthy that 
the increase in the number of diagnoses (n=500) in the 25-year study period, which took place 25 years 
after the previously reported study done in Cape Town with only 168 PID-diagnosed patients over a 
26-year period.(3) The increase is probably due to improved diagnostic ability and recording, but 
prevalence and the burden of PID is probably still underestimated in South Africa.(44) Another South 
African publication documented the lack of dedicated immunologists and unavailability of a screening 
programme in South Africa.(1)  
The median age of patients at diagnosis, namely 5 years, was older than that of patients in other 
comparative studies in Iran (median age of 3 years and 6 months) and in both Oman and Tunisia (median 
age of 2 years).(28)(45)(46) The majority of patients (60%) presented with respiratory symptoms. This 
was a similar finding to the earlier Cape Town study (95,4%), as well as the report from Iran (33.5%) 
and Oman (47%).(45)(46)(3) Only 3% of patients in the present study were referred for evaluation 
because of a family history, despite family history being one of the strongest predictors of PID.(30) The 
predominantly male distribution (55%) was similar to studies in the Middle East (61%), North Africa 
(58%), Europe (60,8%) and the United States of America (58%).(28)(45) (47)(48). The male 
predominance could be explained by some PID conditions that are inherited in a X-linked pattern. 
The diagnostic spectrum compares to reports from Europe, the United States of America, Latin 
America, China and the Middle East with regard to the most common PID being antibody 
deficiency.(49)(50)(51)(26)(52)(48)(53) The most common specific disorder was common variable 
immunodeficiencies (9,2%), which was also similar to the findings in the previous reports from Cape 
Town (11,3%), Egypt (18,7%) and Europe (20,7%), while severe combined immunodeficiency was 
more common in Iran, Saudi Arabia and Tunisia. In Oman, phagocytic disorders were 
predominant.(54)(3)(26)(45)(51)(28)(47) A surprising finding of this study was the high percentage of 
complement deficiencies (10,8%) in comparison to other studies in Europe (1%), the United States 
(2,6%), Latin America (2,8%), Tunisia (0,4%), Iran (2,4%) and Oman (6%).(28)(45)(46)(48)(55) The 
high percentage of complement deficiencies is probably attributable to the special research interest in 






The number of African and mixed-race patients referred for evaluation of suspected PIDs has 
dramatically increased in the past two decades, but has still been severely underrepresented in terms of 
the racial demography of South Africa. The increase could be due to an improved awareness and 
diagnosis of PIDs. Caucasian patients have had mostly antibody deficiency (60%), which is similar to 
two reports from the USA.(56)(57)  
There is limited information regarding the Asian population and PIDs in South Africa. In a report by 
Wang et al(53) on the distribution and clinical features of primary immunodeficiency diseases in 
Chinese children from 2004 to 2009, the findings similar to this study included a male predominance 
(5.29:1), with antibody deficiency disease as the most common category (48,2%), with pneumonia 
being the most common manifestation. The spectrum of PID included well-defined immunodeficiency 
syndromes (20,5%), combined T and B cell immunodeficiencies (16,9%), congenital defects of 
phagocyte number and/or function (10,8%) and diseases of immune dysregulation (3,1%). 
Agammaglobulinemia was the most frequent disease type.(53) 
Autoinflammatory conditions were mostly seen in the Caucasian population. The African patients 
(11,6%) and mixed race (4,8%) mostly had complement deficiencies (4% and 10% respectively) (of 
which hereditary angioedema was the most common diagnosis), followed by antibody deficiency (3% 
and 7%) and combined immunodeficiencies with syndromic features (1% and 2%). There was a smaller 
percentage of congenital defects of phagocyte number, function, or both in South Africa (4,2%) 
compared to 17,5% in Iran, 42% in Oman and 56% in Europe.(46) 
PID is still regarded as a rare disease in South Africa, as it is in the rest of the world, partly because of 
lack of data especially from Africa. A disease is considered rare when it affects fewer than 200 000 
individuals in the United States or fewer than one in 2 000 people in Europe (58). In South Africa, 
which is still a developing country with limited resources for patients with PID, research is limited, 
expertise is sparse and the diagnosed patients are few in number. It is important, however, to advocate 
for better access to specialty care including psychological support to improve quality of life.  
Areas that need development in South Africa include an online national register, national and 
international research collaboration and implementation of formal subspecialty training in clinical 
immunology for paediatric and adult immunologists. Government funding or health insurance needs to 
improve to ensure that patients are entitled to long-term follow up and appropriate essential treatments. 
Awareness and care will also improve if South Africa can establish more specialist PID centres with 
reasonable accessibility for all patients in different provinces. In the context of rare diseases, disease-
specific registries form a vital component of a public health programme, providing data necessary for 
planning services, monitoring public health and improving patient care. Patient registries can help to 
provide the basis for this by collecting data over a longer period of time and by connecting centres 






organisation that started to run an online registry (initiated in 2004). The advantage of this most up-to-
date form of data storage is the ease of accessibility for users worldwide without necessarily needing 
additional technical equipment or software.(59) If a standardised database or register were to be used 
for all patients with PID in South Africa, it would serve as a platform for epidemiological analysis and 
for the review and development of new diagnostic and therapeutic strategies for patients with PID in 
South Africa. The design, realisation, curation and documentation in a database is, however, time 
consuming and requires dedication and funding. A lack of time, funding and manpower thus poses a 
challenge for maintaining a register. 
With the advances in molecular, whole genome and exome sequencing techniques in South Africa, 
additional patients with defects should be identified. A protocol for selecting patients who will need 
molecular or genetic testing would aid in earlier diagnosis of patients with PID. An example of 
improving clinical and genetic data collection by pooling resources and using research collaborations 
is the Asian Primary Immunodeficiency (APID) Network. APID was established in 2009 at the 
University of Hong Kong, and has a genetic diagnostic laboratory. The aim is the promotion of 
knowledge in terms of scientific discovery, clinical management and service needs of PID in Asian 
countries. The genetic diagnostic laboratory has offered free of charge genetic tests for patients from 
over 50 hospitals in mainland China, Taiwan, the Philippines, Singapore, Thailand, Malaysia, Vietnam, 
India and the Kingdom of Bahrain. In 4 years, the APID Network received 1 300 referrals and PID was 
genetically confirmed in 455 patients.(60) 
Newborn screening in 11 programmes in the United States identified a surprisingly high number of 
SCID, namely 1 in 58 000 infants, with high survival due to early diagnosis and treatment.(61) Newborn 
screening for the detection of severe forms of PID manifest through T and/or B cell lymphopenia using 
T cell receptor excision circles (TREC), and kappa-recombining excision circles screening has been 
established in many countries.(62) Unfortunately South Africa does not have a newborn screening 
protocol for PIDs. A review of the national registry for patients with PID maintained by the United 
States Immunodeficiency Network (USIDNET) found that 28% of African-American patients had 
recorded neutropenia, while only 17% of Caucasians and 2% of Asian/Pacific Islanders were 
neutropenic (p=0.005).(63) Further investigation for PID in African patients with neutropenia in South 
Africa could potentially increase the diagnostic yield of PIDs in this racial group. 
Even in South Africa, with limitations on healthcare spending, it was reported that hematopoietic stem 
cell transplantation is feasible and offers many patients the opportunity for cure or long-term 
survival.(64) The ESID keeps record of treatment modalities (e.g. immunoglobulin therapy and stem 
cell treatment) as well as whether it is administered as in- or outpatient.(55) These data aid in assessment 
of quality of life. If treatment modalities are recorded in a similar manner in South Africa, it would aid 






5.2 Limitations and strengths of this study 
Not all hospitals and medical practitioners in South Africa contribute to the South African PID Registry, 
which leads to under-reporting of PIDs. Furthermore, the division of private and state medical care 
causes a scattered network of information regarding PID incidence and prevalence. 
A shortcoming of this study is the underrepresentation of less well known or less severe categories of 
PIDs owing to suspected lack of reporting or lack of enough criteria to confirm a diagnosis for inclusion 
in the South African PID Registry. There is still a serious lack of data on African patients and their 
profiles. There is also a lack of accuracy of diagnoses in the hard copy notes, and definite molecular 
diagnoses of patients only emerged in the past 10 years (mostly funded by research collaborations). 
Owing to the limited availability of genetic testing, most of the patient diagnoses were based on clinical 
grounds.  
Notwithstanding these shortcomings, this study provides a retrospective review of the local 
epidemiology of PID in the Western Cape and adds to the existing knowledge on PIDs in South Africa. 
A strength of the study lies in having one dedicated reviewer to review the data and similarities and 
differences found in the comparative review of the PID profile in the Western Cape with international 
and African countries.  
5.3 Conclusions 
This study is the first review of Tygerberg Hospital’s Immunology Service, which is also the main 
feeder for the national PID Registry, and described the spectrum of patients referred to a single tertiary 
centre in South Africa. It includes findings regarding mode of presentation and types of PIDs, and the 
results were found to be similar to the results from other developing countries, except that the Western 
Cape had the highest reported frequency of complement deficiencies (specifically hereditary 
angioedema) in the world.  
The Western Cape median age of diagnosis was older, compared to other developing countries, and 
attempts should be made to improve awareness and encourage early diagnosis. Further significant 
aspects noted in the study were the lack of data on African patients and their profiles, the importance of 
a PID suggestive family history, and the need to consider PID as a differential diagnosis in HIV-negative 
patients with chronic or unusual respiratory disease. 
5.4 Future research 
Though telephonic and email consultations, extent of special investigations and treatment provided 






paediatric immunology service. The availability of special investigations and the treatment of PIDs in 
South Africa could be areas for future research. Such research would give an indication of whether 
improvements have been made in the referral system and would furthermore assess figures on the 
morbidity and mortality of patients with PID in this country. Electronic data capturing with guidance 
on salient aspects in history and investigations into when patients are referred will also improve the 
service and subsequent data analysis.   
The rapid drop in price of molecular diagnostics and improved data analysis, as also the ease with which 
DNA samples can be shipped in countries with extremes of temperature, will make an attractive second-
line investigation into PID in the future. Furthermore, the comprehensive history of patients with 
suspected PID, together with genetic counselling, is of paramount importance for targeted and ethical 
molecular investigation. Molecular diagnosis of PID in South Africa should improve with the increased 
availability of these tests. 
Improved awareness of PID and registration of patients with PID will provide a basis for the 
implementation of government policies to improve access to treatment and supportive care for patients 








1. Data collection sheet 
2. IUIS classification (April 2014) 







1. Data collection sheet 
2. # Variable / Field Name Field Label Field Note 
Field Attributes (Field Type, Validation, 
Choices, Calculations, etc.) 
Instrument: Record number (record_number) 
1 record_id Record ID text 
2 surname_name Surname, Name text, Required, Identifier 
3 folder_number Folder number text, Identifier 
4 dob Date of birth text (date_dmy, Min: 1800-01-01), 
Identifier 





6 geographic_origin Geographic 
origin 
radio 
1 Northern Province/ Limpopo 





7 Northern Cape 
8 Western Cape 
9 Eastern Cape 
10 Not South African 
 












9 iuis_category IUIS category checkbox, Required 
1 iuis_category___1 Combined 
immunodeficiencies 




3 iuis_category___3 Predominantly 
antibody 
deficiencies 







5 iuis_category___5 Congenital defects 
of phagocyte 
number, function or 
both 
6 iuis_category___6 Defects of innate 
immunity 
7 iuis_category___7 Autoinflammatory 
disorders 
8 iuis_category___8 Complement 
deficiencies 




10 iuis_category___10 None of the above 
 







2 Asplenia syndrome (Ivemark syndrome) 
3 Ataxia telangiectasia (ATM) 
4 Autoimmune lymphoproliferative 
syndrome (ALPS) 
5 Autoimmune polyendocrinopathy 
candidiasis ectodermal dystrophy 
(APECED/ APS1 with CMS) 
6 Barth syndrome 
7 Bloom syndrome 
8 Cartilage hair hypoplasia (CHH) 
9 Chronic mucocutaneous candidiasis 
(CMC) 
10 Complement component 2 deficiency 
11 Complement component 3 deficiency 
(C3) 
12 Class switch recombination (CSR) 
defects and hyper- immunoglobulin M 
(HIGM) syndromes 
13 Chediak Higashi syndrome (CHS) 
14 Chronic granulomatous disease (CGD) 
15 Clericuzio-type poikiloderma with 
neutropenia syndrome 
16 COHEN syndrome 
17 Combined immunodeficiency (CID) 
18 Common variable immunodeficiency 
disorders (CVID) 
19 Congenital neutropenia 
20 Cyclical neutropenia 
21 Defects of TLR/NFkappa-B signalling 
22 Defects with susceptibility to 






23 Deficiency of specific IgG (Specific 
antibody deficiency- SPAD) 
24 DiGeorge syndrome 
25 Dyskeratosis congenita 
26 Factor D deficiency 
27 Familial hemophagocytic 
lymphohistiocytosis syndromes (FHLH) 
28 FOXP3 deficiency (IPEX) 
29 Glycogen storage disease type 1b 
(GS1b) 
30 Griscelli syndrome type 2 
31 Hereditary angioedema (C1 inh) 
32 Hermansky-Pudlak syndrome (type 2) 
33 HLA class I deficiency 
34 HLA calss II deficiency (MHC2) 
35 Hoyeraal-Hreidarsson syndrome 
36 Hyper IGE Syndromes (HIES) 
37 IgA with IgG subclass deficiency 
38 Immunodeficiency centromeric 
instability facial anomalies syndrome 
(ICF) 
39 IPEX-like disease 
40 Isolated IgG subclass deficiency 
41 Isolated congenital asplenia 
42 Mannose-binding lectin deficiency 
(MBL) 
43 Nijmegen breakage syndrome 
44 Omenn syndrome 
45 Partial albinism and immunodeficiency 
syndrome 
46 Properdin P factor complement 
deficiency (PFC) 
47 Schimke disease 
48 Seckel syndrome 
49 Selective CD4 cell deficiency 
50 Selective IgA deficiency 
51 Selective IgM deficiency 
52 Severe combined immunodeficiency 
(SCID) 
53 Shwachman-Diamond-syndrome 
54 Thymoma with immunodeficiency 
55 Transient hypogamma-globulinaemia of 
infancy 
56 Warts hypogammaglobulinemia 
infections and myelokathexis (WHIM) 






58 X-linked lymphoproliferative syndrome 
(XLP) 
59 Unclassified antibody deficiency 
60 Unclassified phagocytic disorders 
61 Unclassified disorders of immune 
dysregulation 
62 Unclassified defects of innate immunity 
63 Unclassified complement deficiencies 
64 Unclassified autoinflammatory disease 
65 Unclassified syndromic 
immunodeficiencies 
66 Unclassified immunodeficiencies 
67 None of the above 
 








12 diagnosis_other Diagnosis 
(other) 
notes 
13 referral_date Date of referral text (date_dmy) 
14 source_of_referral Source of 
referral 
dropdown (autocomplete) 
1 Paediatrician Tertiary Hospital 
2 Paediatrician other than Tertiary 
3 Physician in Tertiary hospital 
4 Physician other than tertiary 
5 General practisioner 
6 Other- eg Patient support Group and 
Pathologist 
 





16 date_of_diagnosis Date of 
diagnosis 
text (date_dmy) 
17 age_diagnosis_years Age at 
diagnosis(years) 
text 
18 age_diagnosis_months Age at diagnosis 
(months) 
text 
19 presenting_features Presenting 
features 
checkbox 
1 presenting_features___1 Respiratory 
2 presenting_features___2 Skin 
infections/ 
eczema 
3 presenting_features___3 Pyrexia 
4 presenting_features___4 GIT related 
5 presenting_features___5 Swelling of 
body 






7 presenting_features___7 Septicaemia 
































24 sa_pid_register Registered on 
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